Cilbactam 1.5
Ampicillin (1gm) + Sulbactam (500mg)
About this product
Broad single-agent coverage against gram-positive, gram-negative, and anaerobic infections, including skin, intra-abdominal, and gynaecological infections such as PID and endometritis.
Overview
Cilbactam 1.5 combines ampicillin with the beta-lactamase inhibitor sulbactam, restoring effectiveness against many resistant strains. It offers broad, practical cover spanning Gram-positive, Gram-negative, and anaerobic organisms — a cost-effective choice for mixed surgical, gynaecological, and respiratory infections.
Indications
Related Products
Aztronaz 1g
Aztreonam (1gm)
Targeted gram-negative coverage against E. coli, Klebsiella, and Pseudomonas for serious UTI, respiratory, intra-abdominal, gynaecological, skin, and bloodstream infections.
Mertazo 1.5
Meropenem (1gm) + Tazobactam (500mg)
Dependable broad-spectrum coverage for resistant hospital infections, including HAP/VAP, complicated intra-abdominal infections, complicated UTI/pyelonephritis, and severe sepsis pending culture guidance.
Partner With Schemic Concepts
Engineer better health outcomes with precision-driven pharmaceuticals
Healthcare is moving toward greater digital integration and evidence-based care. Schemic Concepts is built to move with it